Medexus Pharmaceuticals - MEDXF Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $2.38
  • Forecasted Upside: 226.41 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.73
▲ +0.03 (4.30%)

This chart shows the closing price for MEDXF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medexus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEDXF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEDXF

Analyst Price Target is $2.38
▲ +226.41% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Medexus Pharmaceuticals in the last 3 months. The average price target is $2.38, with a high forecast of $2.75 and a low forecast of $2.00. The average price target represents a 226.41% upside from the last price of $0.73.

This chart shows the closing price for MEDXF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Medexus Pharmaceuticals. This rating has held steady since July 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/22/2022Canaccord Genuity GroupLower TargetC$3.50 ➝ C$2.75
9/20/2022Raymond JamesDowngradeOutperform ➝ Market Perform$4.50 ➝ $2.00
7/26/2022Raymond JamesInitiated CoverageOutperform
3/2/2022Raymond JamesBoost TargetC$5.50 ➝ C$5.75
2/22/2022Raymond JamesInitiated CoverageOutperform
7/19/2021Roth CapitalInitiated CoverageBuy$6.15
2/24/2021Stifel NicolausBoost TargetBuy$7.25 ➝ $17.50
(Data available from 10/5/2017 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/8/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/8/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Medexus Pharmaceuticals logo
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
Read More

Today's Range

Now: $0.73
Low: $0.71
High: $0.73

50 Day Range

MA: $1.65
Low: $0.68
High: $2.44

52 Week Range

Now: $0.73
Low: $0.59
High: $3.50

Volume

3,657 shs

Average Volume

10,311 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Medexus Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Medexus Pharmaceuticals in the last twelve months: Canaccord Genuity Group Inc., and Raymond James.
View the latest analyst ratings for MEDXF.

What is the current price target for Medexus Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Medexus Pharmaceuticals in the last year. Their average twelve-month price target is $2.38, suggesting a possible upside of 226.4%. Canaccord Genuity Group Inc. has the highest price target set, predicting MEDXF will reach $2.75 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $2.00 for Medexus Pharmaceuticals in the next year.
View the latest price targets for MEDXF.

What is the current consensus analyst rating for Medexus Pharmaceuticals?

Medexus Pharmaceuticals currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MEDXF, but not buy more shares or sell existing shares.
View the latest ratings for MEDXF.

What other companies compete with Medexus Pharmaceuticals?

How do I contact Medexus Pharmaceuticals' investor relations team?

Medexus Pharmaceuticals' physical mailing address is 1, Place du Commerce, Verdun, QC H3E. The company's listed phone number is (514) 344-8765. The official website for Medexus Pharmaceuticals is www.medexus.com. Learn More about contacing Medexus Pharmaceuticals investor relations.